Suven Life Sciences today said that their third new chemical entity (NCE) SUVN-D4010 has commenced phase-1 clinical trial in the US. The NCE is a potential drug for treatment of cognitive dysfunction associated with Alzheimer's disease and other dementia. ALSO READ: Suven Life Sciences secures patents in China, Mexico and SA
"We are very pleased that the third compound from our pipeline of molecules in CNS has moved into a clinical trial that is being developed for cognitive disorders in Alzheimer's and Schizophrenia, a high unmet medical need which has huge market potential globally," Venkat Jasti, CEO of Suven said in a statement.
Hyderabad-based Suven Life Sciences is a biopharmaceutical company focused on discovering, developing and commercialising novel pharmaceutical products. Suven has three clinical stage compounds including a phase-2 initiated candidate.